Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 83.12% is in line with its 5-year average of 88.27%, near the low end of its 5-year range (77.94%–96.39%).
0.27% below its 12-month average of 83.35%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 84.11%.
GROSS MARGIN
83.12%
GROSS MARGIN AVG TTM
83.35%
GROSS MARGIN AVG 3Y
85.42%
GROSS MARGIN AVG 5Y
88.27%
GROSS MARGIN AVG 10Y
91.64%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.27%
CURRENT VS 3Y AVG
-2.69%
CURRENT VS 5Y AVG
-5.84%
CURRENT VS 10Y AVG
-9.29%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.87%
vs the sector median at left
Ultragenyx Pharmaceutical Inc.
Market Cap
$1.43B
Gross Margin
83.12%
TTM Avg
83.35%
3Y Avg
85.42%
5Y Avg
88.27%
Market Cap
$1.44B
Gross Margin
17.33%
TTM Avg
13.16%
3Y Avg
12.65%
5Y Avg
13.31%
Market Cap
$1.41B
Gross Margin
98.97%
TTM Avg
9.74%
3Y Avg
-353.69%
5Y Avg
-246.22%
Market Cap
$1.40B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
75.15%
5Y Avg
50.10%
Market Cap
$1.40B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.46B
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
25.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | $1.43B | 83.12% | 83.35% | 85.42% | 88.27% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 17.33% | 13.16% | 12.65% | 13.31% |
| Certara, Inc. (CERT)vs › | $1.45B | 58.33% | 60.70% | 60.53% | 60.29% |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 98.97% | 9.74% | -353.69% | -246.22% |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | 100.00% | 100.00% | 75.15% | 50.10% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 0.00% | 0.00% | 0.00% | 0.00% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.39B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 0.00% | 50.00% | 25.00% | 25.00% |
| GH Research PLC (GHRS)vs › | $1.47B | 0.00% | 0.00% | 0.00% | 0.00% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.47B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
83.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 84.11% |
| 2026-03-31 | 77.94% |
| 2025-12-31 | 85.99% |
| 2025-09-30 | 82.50% |
| 2025-06-30 | 86.18% |
| 2025-03-31 | 79.42% |
| 2024-12-31 | 89.75% |
| 2024-09-30 | 84.93% |
| 2024-06-30 | 85.53% |
| 2024-03-31 | 83.89% |
| 2023-12-31 | 90.54% |
| 2023-09-30 | 88.79% |
| 2023-06-30 | 90.85% |
| 2023-03-31 | 87.80% |
| 2022-12-31 | 94.85% |
| 2022-09-30 | 90.48% |
| 2022-06-30 | 90.74% |
| 2022-03-31 | 92.37% |
| 2021-12-31 | 95.79% |
| 2021-09-30 | 94.89% |
| 2021-06-30 | 96.39% |
| 2021-03-31 | 94.78% |
| 2020-12-31 | 94.01% |
| 2020-09-30 | 97.12% |
| 2020-06-30 | 97.08% |
| 2020-03-31 | 109.65% |
| 2019-12-31 | 85.65% |
| 2019-09-30 | 89.60% |
| 2019-06-30 | 96.83% |
| 2019-03-31 | 97.51% |
| 2018-12-31 | 96.88% |
| 2018-09-30 | 97.68% |
| 2018-06-30 | 98.90% |
| 2018-03-31 | 97.89% |
| 2017-12-31 | 99.96% |
| 2017-09-30 | -30411.11% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | -1014820.00% |
| 2016-09-30 | -43783.78% |
| 2016-06-30 | -254794.12% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
| 2012-12-31 | 0.00% |
